On March 28, 2024, Bristol-Myers Squibb Company has filed a definitive proxy statement soliciting proxies and urged the shareholders to vote against the shareholder proposal from Kenneth Steiner, requesting the Company board of directors to adopt an enduring policy, and amend the governing documents as necessary in order that 2 separate people hold the office of the Chairman and the office of the CEO at its annual general meeting of shareholders scheduled to be held on May 7, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.85 USD | +0.34% | -8.34% | -12.59% |
Apr. 26 | S&P 500 Q1 earnings estimated growth improves; stocks up for week | RE |
Apr. 26 | Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.59% | 90.92B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Bristol-Myers Solicits Proxies from the Shareholders